Authors: Fuad Shaikh, Rabia Arshad , Nasim Karim
Abstract
To evaluate usefulness of Rapid3 Score and Grip Strength Test in assessing therapy response in rheumatoid arthritis. Material and Methods: A 24-week, single-blind, study was carried out on 274 patients, aged 29-69 years, diagnosed with rheumatoid arthritis. They were divided into two groups; one received tablet Methotrexate whereas the other received tablet Leflunomide. Rapid3 score and Grip Strength Test were recorded at initial visit and follow-ups. Rapid 3 score indicates degree of patients’ impaired functional capacity, pain intensity and opinion of general well-being. Grip strength test shows the extent to which patients can compress a partially inflated, aneuroid, sphygmomanometer cuff in their palms. Results: Rapid3 score improved from a baseline of 8.25 to 1.79 units in the Methotrexate group and from 8.35 to 1.63 units in the Leflunomide group at 24 weeks (p< 0.001). Remission was achieved in 26% of patients on Methotrexate and in 27% of patients using Leflunomide. Grip Strength rose to 153.02 mm of Hg from a baseline of 69.70 in the right hand and to 151.10 mm of Hg from 68.62 in the left hand in patients using Methotrexate whereas it rose to 154.04 mm of Hg from a baseline of 71.10 in the right hand and to 151.53 mm of Hg from 70.58 in the left hand in patients using Leflunomide [p< 0.001]. Conclusion: Rapid3 score and Grip Strength test are credible, non-invasive, cost-effective, functional tools for assessing therapy response in rheumatoid arthritis.
Keywords: Rheumatoid arthritis, rapid3 score, grip strength test, non-invasive tests
